Pharmaceutical Technology

FEBRUARY 22, 2023

Amgen could be the winner of a high-stakes patent spat with Sanofi as tensions run high weeks before the March 27 US Supreme Court hearing. While some courts were previously on Sanofi’s side, it is possible that Amgen’s case could win this time, some legal experts say. Both drugs come with a high price tag.

Antibody 262

Antibody Drugs Sales Protein 262

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. For example, in Sweden, the proposed arrangement for Sanofi / Regeneron’s Dupixent (dupilumab) included a tripartite price negotiation involving Sanofi, the Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV), and local councils.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130

Antibody DNA Development Vaccination 130

Delveinsight

FEBRUARY 23, 2021

The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform. The approval is granted to Sanofi and Regeneron Pharmaceuticals.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52

XTalks

MARCH 22, 2023

Two years later, Sanofi dwarfed the Pfizer-Pharmacia acquisition by buying out fellow French drugmaker Aventis for $65 billion. In addition, nearly half of all new drugs launched between 2020 and 2021 came with a price tag of $150,000 per year, or more.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

Pharmaceutical Technology

JANUARY 27, 2023

On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. The post Sanofi offers refunds for Cablivi in novel model for rebates appeared first on Pharmaceutical Technology.

Manufacturing 130

Manufacturing Drugs Research Analyst FDA Approval 130

pharmaphorum

NOVEMBER 19, 2021

Two casualties of the Pfizer/BioNTech and Moderna success, however, have been Sanofi and CureVac, both firms dropping their mRNA shots. Disappointing late-stage trials of CureVac’s jab meant there was no competitive advantage, while Sanofi said the dominance of current vaccines made penetration in the market difficult.

Sales 137

Sales Vaccination Vaccine Marketing 137